Kura Oncology (NASDAQ:KURA) Shares Gap Up – Should You Buy?

Kura Oncology, Inc. (NASDAQ:KURA) shares gapped up prior to trading on Tuesday . The stock had previously closed at $17.56, but opened at $18.30. Kura Oncology shares last traded at $18.68, with a volume of 40,820 shares changing hands.

Wall Street Analysts Forecast Growth

KURA has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. UBS Group assumed coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price on the stock. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Stock Performance

The firm’s 50 day moving average is $18.71 and its two-hundred day moving average is $19.99. The stock has a market capitalization of $1.47 billion, a PE ratio of -8.08 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in Kura Oncology during the 3rd quarter worth approximately $25,000. SG Americas Securities LLC acquired a new position in Kura Oncology during the 1st quarter worth approximately $110,000. Quarry LP acquired a new position in Kura Oncology during the 2nd quarter worth approximately $196,000. Entropy Technologies LP acquired a new position in Kura Oncology during the 1st quarter worth approximately $218,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Kura Oncology by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after acquiring an additional 5,788 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.